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Microbiota coexists in true symbiosis with the host playing pivotal roles as a key
element for well-being and health. Exopolysaccharides from lactic acid bacteria are an
alternative as novel potential prebiotics that increase microbiota diversity. Considering
this, the aim of the present work was to evaluate the capacity of the EPS produced
by two L. paracasei strains isolated from kefir grains, to be metabolized in vitro by
fecal microbiota producing short chain fatty acids. For this purpose, fecal samples
from healthy children were inoculated in a basal medium with EPS and incubated
in anaerobiosis at 37◦C for 24, 48, and 72 h. DGGE profiles and the production
of SCFA after fermentation were analyzed. Additionally, three selected samples were
sequenced by mass sequencing analysis using Ion Torrent PGM. EPS produced by
L. paracasei CIDCA 8339 (EPS8339) and CIDCA 83124 (EPS83124) are metabolized by
fecal microbiota producing a significant increase in SCFA. EPS8339 fermentation led
to an increment of propionate and butyrate, while fermentation of EPS83124 increased
butyrate levels. Both EPS led to a profile of SCFA different from the ones obtained
with inulin or glucose fermentation. DGGE profiles of 72 h fermentation demonstrated
that both EPS showed a different band profile when compared to the controls; EPS
profiles grouped in a cluster that have only 65% similarity with glucose or inulin profiles.
Mass sequencing analysis demonstrated that the fermentation of EPS8339 leads to an
increase in the proportion of the genera Victivallis, Acidaminococcus and Comamonas
and a significant drop in the proportion of enterobacteria. In the same direction, the
fermentation of EPS83124 also resulted in a marked reduction of Enterobacteriaceae
with a significant increase in the genus Comamonas. It was observed that the changes in
fecal microbiota and SCFA profile exerted by both polymers are different probably due to
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differences in their structural characteristics. It can be concluded that EPS synthesized
by both L. paracasei strains, could be potentially used as bioactive compound that
modify the microbiota increasing the production of propionic and butyric acid, two
metabolites highly associated with beneficial effects both at the gastrointestinal and
extra-intestinal level.
Keywords: prebiotics, probiotics, microbiota, short chain fatty acids, exopolysaccharide, lactic acid bacteria
INTRODUCTION
Microbiota coexists in true symbiosis with the host playing
pivotal roles as a key element for well-being and health
(Weiss and Hennet, 2017; Cani, 2018). The relevance of
microbial ecology at the intestinal level on health status led
the "International Scientific Association for Probiotics and
Prebiotics" (ISAPP) to propose the concept of "normobiosis" to
characterize a healthy microbiota where microorganisms with
potential benefits for health predominate in number compared
to potentially harmful ones, in contrast to "dysbiosis" in which
one or a few potentially harmful microorganisms are dominant
creating a disease situation (Roberfroid et al., 2010; Thursby
and Juge, 2017). The intestinal microbiota responds to multiple
stress factors such as diet, antibiotic use, inflammation of the
intestinal tract and/or infection of the host with enteric pathogens
(Conlon and Bird, 2015; Shen and Wong, 2016; Durack and
Lynch, 2019). A stable microbiota with an adequate balance is
necessary to maintain the integrity of the epithelial barrier, the
immune balance and the physiological control of inflammatory
processes. In turn, a "dysbiotic" microbial composition leads
to an intestine with loss of integrity of the epithelial barrier
which favors bacterial translocation and inflammation (Round
and Mazmanian, 2009; Tsai et al., 2019). In this context, the use
of diet as a basis for modifying the microbiota has re-emerged
in recent years, validating the ancient concepts of the relevant
role of nutrition in health (Requena et al., 2018). Therefore, the
interest for probiotics or novel sources of prebiotic compounds
is increasing all over the world (Ewaschuk and Dieleman, 2006;
Gareau et al., 2010; Alagón Fernández del Campo et al., 2019;
Venema et al., 2020).
Prebiotics has recently been defined as “a substrate that is
selectively utilized by host microorganisms conferring a health
benefit,” expanding the concept of prebiotics to include non-
carbohydrate substances with healthy effects even at distal
sites (Gibson et al., 2017). Prebiotics has been studied for the
modulation of infant microbiota on account of their long-
lasting effects, extended even after the administration period.
Otherwise, they have low risk of serious adverse effects and
are easy to administrate in infant foods (Miqdady et al., 2020).
The administration of prebiotics in children is associated with
a number of beneficial health outcomes, such as reduced risk
of some allergic reactions, reduced inflammation and risk
of infections (Miqdady et al., 2020). Additionally, they may
contribute to reduce the risk of development of dysbiosis
associated chronic diseases like intestinal bowel disease, irritable
bowel syndrome, and type 1 diabetes (Milani et al., 2017).
Oligosaccharides present in human milk (HMO) as well as
galactooligosacharides (GOS) and fructooligosaccharides (FOS)
usually included in infant milk formulae are the most studied
prebiotics used for children, which have been proved to induce
specific changes in the composition and metabolic activity of
the intestinal microbiota (Braegger et al., 2011; Parker et al.,
2020). The end products of prebiotics fermentation are acetic,
propionic and butyric acids, lactic acid, hydrogen, methane
and carbon dioxide (Louis et al., 2014). Lactate and short
chain fatty acids (SCFA) are used by host cells as an energy
source. They participate as mediators of the host response
since they are able to interact with G protein-coupled receptors
(GPR43, GPR41, GPR81, and GPR109A) modulating positively
or negatively the activity of enzymes that originate second
messengers. Besides, some SCFA act as epigenetic regulators by
inhibition of histone deacetylases (HDAC) (Kasubuchi et al.,
2015). In addition, they can promote the integrity of the epithelial
barrier function by reinforcing tight junctions (Morrison and
Preston, 2016) and play a role in the regulation of inflammatory
response mediated by inflammasome (Offermanns, 2014). They
participate in the absorption of water and electrolytes (Vinolo
et al., 2011; Koh et al., 2016) and are relevant not only in the
context of gastrointestinal pathologies (Louis and Flint, 2009,
2017; Thorburn et al., 2014) but also of extraintestinal diseases
(Durack and Lynch, 2019).
Fermented foods containing lactic acid bacteria, whether
probiotic or not, are the main source of microorganisms
that temporarily complete the microbial community of the
gastrointestinal tract, constituting what is known as the transient
microbiome (Koh et al., 2016) that can reach 1010–1011 viable
bacteria ingested per day, depending on the eating habits of
each individual (Plé et al., 2015; Rezac et al., 2018). Some
lactic acid bacteria produce exopolysaccharides (EPS) during
fermentation, which, when ingested with the fermented product,
can serve as a substrate for commensal bacteria (Ryan et al.,
2015), stimulating the development of beneficial microorganisms
at the intestinal level and the production of bioactive metabolites
(Salazar et al., 2011; Hamet et al., 2016). Being selectively
fermented by the microbiota, exopolysaccharides from lactic acid
bacteria constitute an alternative as novel potential prebiotic
compounds (Balzaretti et al., 2017; Lynch et al., 2018).
Kefir is an artisanal fermented food obtained by milk
fermentation with the complex microbiota present in kefir grains.
This fermented milk has a long tradition of offering health
benefits such as antimicrobial activity, stimulation of immune
system, anti-inflammatory, anti-obesity, cholesterol lowering
and antioxidant effects, improvement of lactose tolerance, and
enhancement of intestinal bacterial microbiota, among others.
Lactic acid bacteria, yeast and acetic acid bacteria of different
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genera, species and even strains coexist in this product and they
and/or the metabolites synthesized by them during fermentation
could contribute to beneficial health properties attributed to
its consumption (Garrote et al., 2010; Bengoa et al., 2019b).
Lactobacillus paracasei CIDCA 8339 and CIDCA 83124 are EPS-
producing strains isolated from Argentine kefir grains (Hamet
et al., 2013; Bengoa et al., 2018a) that have good technological
properties and fulfill safe requirement for food application
of Argentine and European regulation (Bengoa et al., 2019a).
L. paracasei strains produce EPS both in milk (Hamet et al., 2015)
and culture media (Bengoa et al., 2018a). Additionally, it has
been demonstrated that these strains present potential probiotic
properties like the adhesion ability to intestinal epithelial cells
which is increased after passage through the gastrointestinal tract
(Bengoa et al., 2018b) and the protective effect against Salmonella
infection in vitro (Zavala et al., 2016).
Considering that microorganisms’ metabolites may contribute
to health properties of the fermented product, the aim of the
present work was to evaluate the capacity of the EPS produced
by L. paracasei CIDCA 8339 and CIDCA 83124 in milk to
be metabolized in vitro by fecal microbiota producing short
chain fatty acids.
MATERIALS AND METHODS
Microorganisms, Growth Conditions, and
Fermented Milks Production
L. paracasei CIDCA 8339 and CIDCA 83124 were grown in
MRS broth (Difco Laboratories, Detroit, MI, United States)
under aerobic conditions at 30◦C for 24 h. For fermented milks
production, 10 mL of an active culture of the corresponding
L. paracasei strain containing ≈ 1 × 109 CFU/mL were
inoculated in 1,000 mL of UHT low-fat milk (La Serenísima,
Mastellone Hnos S.A, Argentina) and then incubated in aerobic
conditions at 30◦C for 24 h.
Exopolysaccharide Obtainment
EPS extraction from the fermented milk was performed
according to Rimada and Abraham (2003). Fermented milks
(500 mL) were heated for 30 min at 100◦C to promote the
detachment and dissolution of the polysaccharide bound to
the cells and the inactivation of enzymes that could hydrolyze
EPS. Trichloroacetic acid 8% (Ciccarelli, Santa Fe, Argentina)
was added to precipitate proteins and the samples were then
centrifuged at 10,000 × g for 20 min at 20◦C in an Avanti J25
centrifuge (Beckman Coulter Inc., Carlsbad, CA, United States).
The EPS suspended in the supernatant was precipitated by adding
two volumes of ethanol per volume of supernatant. Finally, the
samples were dialyzed for 48 h at 4◦C with stirring through
a 1 kDa cut-off dialysis membrane (Spectra/Por, Spectrum
laboratories, CA, United States) to remove lactose residues.
In order to evaluate samples purity, the protein content was
determined qualitatively by the Bradford method (Bradford,
1976). Thin layer chromatography (TLC) was used to determine
the absence of lactose and other simple sugars in the EPS
samples. EPS were finally lyophilized and preserved at room
temperature until use. EPS extraction was performed from two
independent cultures.
EPS Molecular Mass Determination
Average molecular weight (Mw) was determined by high-
performance size exclusion chromatography using a OH-
PAK SB-805HQ gel filtration column (SHODEX, Kawasaki,
Japan) with refractive index (RI) detection system according
to Piermaria et al. (2008). Samples were filtered through a
0.45 µm membrane (Millipore Corporation, Milford, MA,
United States) and 50 µL of polysaccharide solutions (0.5 g/L
in NaNO3 0.1 M) were injected for each run. Samples elution
was performed at room temperature using NaNO3 0.1 M as
mobile phase with a flow rate of 0.95 mL/min (pressure 120–
130 psi). Dextrans with Mw ranging from 97,000 to 3,800,000 Da
(ALO-2770, Phenomenex, Torrance, CA, United States) were
used as standard.
In vitro EPS Fermentation by Human
Fecal Microbiota
Fermentation assay was carried out using fecal samples from
five healthy children aged between 8 months and 3 years
old. The donors were selected taking into account that they
had an optimal health state (normal anthropometric values,
without overweight, and without previous pathologies), an
omnivorous diet and that they had not consumed antibiotics
in the last 6 months prior to the assay. In addition, a
survey was conducted to the parents in relation to the
aforementioned aspects (Supplementary Figure S1). Samples
were collected by the parents according to the protocol
and with the sterile materials provided and sent to the
laboratory the same day, together with a note of informed
consent in obedience to the protocol approved by the Central
Bioethical Committee, National University of La Plata (May
2017). All of them were kept at 4◦C and processed within
24 h after deposition to guarantee the viability of the
microorganisms present.
For the fecal homogenate, equal amounts of the five samples
(5 g) were suspended into sterile phosphate buffer saline (225 mL)
and mixed to obtain a 1/10 diluted pool (Aguirre et al., 2014).
Homogenates were inoculated to a carbohydrate-free basal
medium (1/10) with the EPS under study as the only sugar
source at a final concentration of 0.3% w/v. The carbohydrate-
free basal medium was formulated according to Salazar et al.
(2008): peptone water 2 g/L, yeast extract 2 g/L, NaCl 0.1 g/L,
K2HPO4 0.04 g/L, KH2PO4 0.04 g/L, MgSO4 0.01 g/L, CaCl2
6H2O 0.01 g/L, NaHCO3 2 g/L, cysteine HCl 2.5 g/L, bile salts
0.5 g/L, and tween 80 2 g/L. The medium was autoclaved and then
1 mL/L of hemin solution (50 mg/ml) and 10 µL/L of vitamin K
previously sterilized by filtration were added.
Samples were incubated for 24, 48, or 72 h at 37◦C in
anaerobiosis using jars (AnaeroPack, Mitsubishi Gas Chemical
Company, Japan) according to Salazar et al. (2008). Controls
without sugar (BM), with glucose (GLU) (Britania, Buenos
Aires, Argentina) and with inulin (INU) (Saporiti, Buenos
Aires, Argentina) in the same concentration (0.3% w/v) were
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included in the experiment. Each fermentation condition was
performed in triplicate. After fermentation, the samples were
centrifuged for 10 min at 10,000 xg, the supernatant was filtered
through a 0.45 µm pore membrane and stored at −20◦C
for SCFA quantification by gas chromatography. The pellets
were stored at −80◦C for the subsequent characterization of
microbial populations.
Determination of Organic Acids by Gas
Chromatography
Chromatographic analysis was carried out using an Agilent
7890a GC system with a DB23 column (Agilent Technologies,
Santa Clara, CA, United States) coupled to a flame detector
(FID). The temperature at the injection port and at the
FID was 250◦C. Helium was used as carrier gas at a flow
rate of 1.6 mL/min. For the run, 1 µL of the sample was
injected with a 1:25 split and a temperature program that
consisted of a ramp from 100 to 200◦C at a speed of 8◦C/min,
keeping constant at 200◦C for 3 min was used. Calibration
curves with standards of glacial acetic acid (1–50 mM),
propionic acid (0.5–20 mM), butyric acid (0.5–20 mM), iso-
butyric acid (0.5–20 mM), and iso-valeric acid (0.5–20 mM)
were prepared (Sigma-Aldrich, San Luis, MO, United States).
Organic acids were identified by comparison to standard
retention times and quantified with the corresponding peak
area using the calibration curve. Differences were statistically
tested using One-way analysis of variance (ANOVA) with
Tukey’s multiple comparison test (p < 0.05) conducted by the
GraphPad Prism R© software.
DNA Isolation
DNA extractions were performed by using a commercial
QIAamp PowerFecal DNA kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. DNA concentration
and quality were determined using a NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, United States). The DNA samples were used for DGGE
analysis and mass sequencing. DNA extracted from pure cultures
of Lactobacillus casei, L. plantarum, L. kefiri, and Bifidobacterium
adolescentis were used as reference strains for DGGE analysis.
Microbiota Evolution Analysis by DGGE
The fecal microbiota evolution during batch fermentations
was analyzed by partial amplification of the 16S rRNA gene
using universal primers 518R and 338F-GC (Table 1). PCR
amplification was performed using Taq polymerase Pegasus (PB-
L Biological Products, Argentina) following the manufactures
TABLE 1 | Primers used in this study.
Primer name Sequence References
338f-GC GCclamp-ACTCCTACGGGAGGCAGCAG Bakke et al., 2011
518r ATTACCGCGGCTGCTG
515 GTGYCAGCMGCCGCGGTAA Caporaso et al.,
2011806 GGACTACNVGGGTWTCTAAT
instruction and using 1 ng/µL of DNA template. The reaction
was carried out in a T100 thermal cycler (Bio-rad laboratories,
Irvine, CA, United States) with the following amplification
program: 94◦C for 5 min; 35 cycles of 94◦C for 30 s, 60◦C
for 45 s and 72◦C for 20 s; and a final extension step at
72◦C for 1 min. The amplification products were analyzed by
electrophoresis in 1% w/v agarose gels with ethidium bromide
and revealed under UV light.
Denaturing-gradient-gel electrophoresis (DGGE) was
performed in a DGGE-2401 analyzer (C.B.S. Scientific Co.,
Del Mar, CA, United States). The PCR products (15 µL) were
seeded in 8 g/100 mL polyacrylamide gels (15 × 20 × 0.075 cm)
in TAE buffer [50X TAE is 2 M Tris, 1 M acetic acid, and
50 mM EDTA (pH 8.0)]. A denaturing gradient of Urea-
Formamide 40–60% (100% corresponds to Urea 7 M and
Formamide 40% v/v) was used to achieve the optimal separation
of the bands corresponding to Eubacteria. Electrophoresis
was carried out at 90 V for 16 h at 60◦C. Gels were then
stained by immersion for 30 min in a 0.1 µL/mL Sybr-Gold
solution (Invitrogen, United States) in TAE buffer and observed
under UV light. Band patterns obtained for each sample were
compered using the Bionumerics 6 program (Applied maths
NV, Sint-Martens-Latem, Belgium). The percentage of similarity
between the samples was calculated using the Dice Similarity
Coefficient and the corresponding UPGMA dendrograms
were constructed.
Mass Sequencing Analysis Using Ion
Torrent PGM
The mass sequencing analysis was carried out in the MR
DNA molecular research laboratory (TX, United States1), based
on established and validated protocols2. Primers 515 and 806
that amplify the V4 variable region of the gene that codes
for 16S rRNA were used (Table 1). For PCR, the HotStarTaq
Plus Master Mix kit (Qiagen, Hilden, Germany) was used
with an amplification program that consisted of 94◦C 3 min,
30 cycles of 94◦C 30 s, 53◦C 40 s, 72◦C 1 min and finally
72◦C 5 min.
The mass sequencing analysis was performed using the Ion
Torrent Personal Genome machine (PGM) system (Thermo
Fisher Scientific, Waltham, MA, United States) following the
manufacturer’s guidelines. The generated data was demultiplexed
and analyzed using a pipeline developed in the MR DNA
molecular research laboratory. Raw data sequencing reads were
quality trimmed using the QIIME suite of tools. Sequences were
depleted of barcodes and primers, followed by removal of short
sequences (<150 bp), sequences with ambiguous base calls and
with homopolymer runs exceeding 6 bp. Noise from sequences
and chimeras were also removed. Sequencing data were grouped
into 3% divergence operating taxonomic units (OTUs) and
taxonomically classified using the BLASTn.NET algorithm with
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RESULTS
EPS Production by L. paracasei Strains
in Milk
EPS production during milk fermentation at 30◦C by L. paracasei
CIDCA 8339 and CIDCA 83124 were about 130–145 and 140–
160 mg of EPS per liter of fermented milk respectively. These
values are within the expected range, since EPS yield by LAB
is normally very low (Ruas-Madiedo et al., 2008; Llamas-Arriba
et al., 2019). Crude EPS isolated from fermented milk with
L. paracasei CIDCA 8339 (EPS8339) and CIDCA 83124 (EPS83124)
were partially characterized by analyzing their molecular weight
distribution (Mw) by gel permeation chromatography. EPS8339
consists of two fractions, a high Mw fraction of about 4 105 Da
and a low Mw fraction of about 1 104 Da. On the other hand,
EPS83124 presents four fractions: a low Mw fraction of 1 104 Da,
an intermediate Mw fraction of 7 104 Da and a high Mw fraction
constituted by two Mw distributions of 7 105 and 6 106 Da.
Evaluation of Fecal Microbiota Evolution
During EPS Fermentation
PCR DGGE profiles were employed to monitor major qualitative
changes in the compositions of microbial groups of fecal
homogenates with and without sugar source added after 24,
48, and 72 h fermentation. DGGE profiles obtained were both
time and sugar source dependent (Figure 1A). After 24 h of
incubation, DGGE profiles of the homogenates fermented in
the presence of EPS8339 and EPS83124 had a high similarity
percentage (77–81%) with respect to the profile obtained for
those grown in the carbohydrate-free basal medium (Figure 1B).
In contrast, profiles of homogenates fermented with glucose
or inulin presented less similarity when compared to the basal
medium. However, after 72 h fermentation, the electrophoretic
profile of the homogenates fermented in the presence of glucose
and inulin resembled more the profile obtained in the basal
medium, while those fermented in the presence of EPS8339 and
EPS83124 showed a different band pattern, locating in a separated
cluster and showing only 60% similarity with the two controls
(GLU and INU). In the presence of glucose or inulin, changes
in microbiota were observed after short fermentation times
indicating the rapid use or assimilation of these sugars by fecal
microorganisms. On the other hand, when EPS8339 and EPS83124
were added to basal medium, the changes in fecal microbiota
occurred after long fermentation times, probably because the
microorganisms need to adapt to this new carbon source.
Dendrogram comparing V3 DGGE profiles obtained with
all growth media assayed at different fermentation times is
shown in Figure 2. Two main clusters that have a similarity
value lower than 48% were observed. One of them joined the
samples corresponding to the 72 h of fermentation in the media
containing EPS8339 and EPS83124 and the other cluster joined
the rest samples grouped in two subclusters. It can be observed
that all the samples obtained after 24 h fermentation joined in
the same subcluster with 71% similarity. The other subcluster
grouped DGGE profiles of the rest of the samples obtained after
48 and 72 h fermentation (61% of similarity). Within this second
subcluster inulin and glucose fermentation after 48 and 72 h
grouped together with 72% of similarity.
Since fecal homogenates fermented during 72 h with EPS8339
and EPS83124 presented the higher differences in the DGGE
band pattern compared to basal medium control, we proceed
to perform a mass sequencing analysis of these samples using
Ion Torrent PGM. Sequence depth performed in the analysis
was adequate since rarefaction curves reached a plateau for
all samples (Supplementary Figure S2). The analysis of alpha
diversity across the samples gave Shannon diversity indices
of 3.79, 3.23, and 3.30 for fermentation in carbohydrate-
free basal medium, basal medium with EPS8339 and basal
medium with EP83124, respectively, indicating high diversity in
the three samples.
Figure 3A shows the distribution of the populations present
in homogenates samples after 72 h fermentation at the phylum
level. The main phyla present in the sample from basal
medium (control) were Proteobacteria (58%), Bacteroidetes
(19%), Firmicutes (17%), and Actinobacteria (2%). Fermentation
of EPS8339 led to an increase in the relative proportion of
Firmicutes (29%) and Lentisphaerae (32%), accompanied by
the decrease in Actinobacteria (0.5%), Proteobacteria (27%)
and Bacteroidetes (8%). On the other hand, fermentation of
EPS83124 caused a reduction of the Actinobacteria (0.7%) and
Bacteroidetes (9%) phyla with an increase in the proportion of
Proteobacteria (73%).
At the genus level, it was observed that, regardless of the
EPS used during the fermentation, the proportion of Klebsiella
and Escherichia (γ-Proteobacteria) were reduced in 6 and 28%
respectively while Bacteroides (Bacteroidetes) dropped in about
11–12% (Figure 3B). Nonetheless, the genera that showed
an increment in their relative abundance after fermentation
were different in both EPS samples, indicating that EPS8339
and EPS83124 are selectively used by different microorganisms
present in fecal microbiota. The proportion of Comamonas
(β-Proteobacteria) increased 6% for EPS8339 and 52% for
EPS83124. This substantial rise of Comamonas genera explains the
difference in the proportion of Proteobacteria phylum previously
mentioned. Furthermore, fermentation of EPS8339 increased the
proportion of the genera Victivallis (33%) and Acidaminococcus
(15%) which correspond to almost the total rise in Lentisphaerae
and Firmicutes phyla evidenced. However, fermentation of
both EPS did not induce major changes in the population of
Lactobacillus and Bifidobacterium.
SCFA Production During EPS
Fermentation by Fecal Microbiota in
Batch Cultures
When analyzing the SCFA levels in the supernatant of fermented
samples, it was evidenced that EPS8339 and EPS83124 are
metabolized by the fecal microbiota producing, consequently, a
significant increase in organic acids with recognized biological
activity (propionate and butyrate) compared to basal medium.
As an example, chromatograms obtained with fecal homogenates
with EPS83124 after different fermentation times are shown in
Supplementary Figure S3. Total SCFA levels increased during
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FIGURE 1 | PCR-based DGGE profiles (A) and the respective dendrograms (B) of fecal homogenates after 24, 48, and 72 h fermentation with EPS8339 (E 8339),
EPS83124 (E 83124), glucose (Glu), inulin (Inu) or without extra sugar added (BM). UF profile corresponds to the one obtained with the unfermented fecal
homogenate and Rs corresponds to reference strains. Lp, Lactobacillus. plantarum; Lk, Lactobacillus kefiri; Lc, Lactobacillus casei; Ba, Bifidobacterium
adolescentis. Dendrograms were obtained by similarity analysis of DGGE profiles using Dice similarity coefficient and UPGMA cluster analysis.
the first 24 and 48 h of incubation with and without external
carbon sources while no changes or a decrease in total SCFA were
observed after 72 h depending on the sugar source. Fermentation
of EPS8339 showed a pattern similar to glucose, where the greatest
increase in SCFA was evidenced at 48 and 72 h. The fermentation
of EPS83124 showed a significant increase after 24 h followed by
a drop after 72 h of fermentation. This reduction could be due to
the fact that some SCFA produced can be then consumed by some
microbial population whose activity was selectively stimulated by
this EPS (Figure 4A).
On account of the levels of each individual SCFA with
biological activity, it was observed that neither EPS8339 nor
EPS83124 significantly increased acetate levels. However, in the
case of EPS83124 a reduction in acetate levels was observed
after 72 h fermentation similar to the results obtained
with carbohydrate-free basal medium (Figure 4B). Regarding
propionate, EPS8339 and glucose fermentation led to a significant
increase of this organic acid at 48 and 72 h, while fermentation
of EPS83124 produced a significant increase in propionate
only at 48 h (Figure 4C). However, the levels of propionate
achieved in the presence of EPS are low compared to inulin
fermentation, since this prebiotic was metabolized by fecal
microbiota producing propionate in concentrations of about
100 mM (Table 2), 10 times higher than those obtained with
EPS8339, EPS83124 or glucose. Furthermore, it is noteworthy
that fermentation of both EPS led to a significant increase in
butyrate at all fermentation times, unlike the results observed
with glucose and inulin where no increment in butyrate was
observed (Figure 4D and Table 2).
These results show that EPS8339 fermentation led to an
increment of propionate and butyrate, while fermentation
of EPS83124 increased butyrate levels. Noteworthy, both EPS
Frontiers in Microbiology | www.frontiersin.org 6 October 2020 | Volume 11 | Article 583254
fmicb-11-583254 October 12, 2020 Time: 15:47 # 7
Bengoa et al. EPS From Lactobacillus paracasei as Microbiota Modulators
FIGURE 2 | UPGMA dendrogram of DGGE profiles of fecal homogenates
microbiota after different fermentation times with EPS8339 (E 8339), EPS83124
(E 83124), glucose (GLU), inulin (INU) or without sugar source added (BM). UF
corresponds to the unfermented fecal homogenate. Dendrogram was
obtained by similarity analysis of DGGE profiles using Dice similarity coefficient
and UPGMA cluster analysis.
generated a different pattern of SCFA than inulin fermentation,
which significantly increases propionate but does not modify
butyrate levels.
In addition, two peaks that elute at 2.63 and 3.25 min
and that were identified as isobutyric and isovaleric acid
respectively, progressively increased with fermentation time
when both bacterial EPS were used as sugar sources (Table 3).
In contrast, these organic acids were not detected when inulin or
glucose were present.
DISCUSSION
The understanding of the mechanisms by which a balanced
microbiome contributes to health has been considerably
expanded in the last years, being the role of the metabolites
one of the focus of research. In particular, SCFA results
of great interest because of their wide variety of health
benefit effects at both intestinal and extra-intestinal level. The
homeostasis of the intestinal microbiota and its corresponding
metabolome depends on the characteristics of the host (age,
sex, genetic background) and on environmental conditions
(stress, medications, gastrointestinal surgery, infectious, and
toxic agents) (Conlon and Bird, 2015). Although microbiota
composition is diverse between individuals in terms of genus
and species, it is dominated by four main phyla: Firmicutes,
Bacteroidetes, Actinobacteria, and Proteobacteria (Hollister et al.,
2014; Hugon et al., 2015) as it was described in the present work.
It is worth to note that the percentage of each phylum described
herein was in concordance to those described previously (Milani
et al., 2017). The early colonization process is crucial for
long-term health benefits having the infant gut microbiota a
main role in modulating risk factors related to adult health
conditions (Milani et al., 2017). It was observed that gut bacterial
microbiome rapidly diversifies over the first years of life in
healthy children while is less diverse in those who develop
allergy or asthma or who are malnourished (Durack and Lynch,
2019). As the composition of the infant’s microbiome can have
a profound effect on adult life, the search of new compounds
that contribute to microbiota modulation for their inclusion
in infant diet results of relevance. In the present work, the
changes in infant fecal microbiota and SCFA levels induced
by EPS8339 and EPS83124 fermentation were studied. For that
purpose, fecal homogenates prepared in a basal medium were
added with different sugars including glucose and inulin that
were used as controls.
Lactic acid bacteria exopolysaccharides are widely studied
for its contribution to food texture. Still, they can also act
as bioactive compounds that are able to exert their effect by
direct interaction to the epithelial cells or indirectly by inducing
specific changes in the composition and metabolic activity of the
intestinal microbiota (Gibson et al., 2017). They are highly diverse
in structure and sugar composition and it has been evidenced
that the biological activity attributed to each biopolymer, such
as the prebiotic potential, is mostly dependent on its molecular
characteristics (Salazar et al., 2016). The fermentation of EPS
synthetized by L. paracasei CIDCA 8339 and CIDCA 83124 led
to changes in fecal microbiota as well as in SCFA profile. These
results indicate in first place, that both EPS are fermentable
by fecal microbiota. However, EPS synthetized by L. paracasei
CIDCA 8339 and CIDCA 83124 in milk showed different
molecular weight distribution. Thus, it is not surprising that the
changes in the fecal microbiota and in SCFA profile exerted by
both polymers are different.
When analyzing the mass sequencing data from 72 h
fermentation samples, it was evidenced that neither EPS8339
nor EPS83124 favored the growth of the genera commonly
consider as beneficial such as Lactobacillus and Bifidobacterium.
Moreover, despite the production of propionate and butyrate
evidenced in these samples, none of the microorganisms
generally associated to the production of those SCFA including
Faecalibacterium prausnitzii, Eubacterium rectale, Eubacterium
hallii, Ruminococcus bromii, Akkermansia municiphilla, and
Roseburia intestinalis (Morrison and Preston, 2016) were
increased after 72 h fermentation when compared to basal
medium. It has been reported that species from the genera
Victivallis, Acidaminococcus and Comamonas, the most favored
by EPS8339 and EPS83124 fermentation, are part of the human
gastrointestinal tract (Jumas-Bilak et al., 2007; Segata et al.,
2012; Samb-Ba et al., 2014; Ricaboni et al., 2017). However, they
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FIGURE 3 | Relative abundance at the phylum level of fecal homogenates fermented for 72 h in the presence EPS8339, EPS83124 or without extra sugar added (BM).
Only phyla with relative abundance higher than 1% in at least one sample were included (A). Differences in bacterial relative abundance at the genus level in fecal
homogenates fermented for 72 h with EPS8339 and EPS83124 in comparison with homogenates fermented 72 h without extra sugar added (BM). Only genera that
showed differences higher than 1% in at least one sample were included (B).
have not been widely studied and their role in the intestinal
microbiota is not clearly yet. Although they do not correspond
to any of the genera commonly associated with the production of
SCFA, it has been reported in the literature that Acidaminococcus
species are capable of producing acetate, propionate and butyrate
(Jumas-Bilak et al., 2007). Furthermore, the genus Victivallis
also contributes to acetate production (Zoetendal et al., 2003).
Despite no significant increase in acetate levels were observed
in the samples fermented in the presence of EPS, it must be
considered that acetate can be used by many gut commensals to
produce propionate and butyrate in a growth-promoting cross-
feeding process (Verkhnyatskaya et al., 2019). Considering this,
the production of acetate by Acidaminococcus and Victivallis
could indirectly promote the production of other SCFA, such
as butyrate through the butyryl-CoA: acetate-CoA transferase
pathway present in some microorganisms of the microbiota
(Louis and Flint, 2017). In this way, these populations could
be directly or indirectly responsible for the significant increase
in butyrate observed during fermentation of EPS8339. The
fermentation of EPS83124 results in an increase of species of the
genera Comamonas such as C. aquatica and C. kerstersii (data
not shown) that do not produce SCFA but instead are able to
consume them (Wauters et al., 2003). Therefore, the pronounced
increase in Comamonas due to EPS83124 fermentation could
explain the significant drop in acetate and butyrate evidenced
after 72 h fermentation. It has been evidenced that the presence
of this genus, that is normally located in the Lieberkühn crypts,
is beneficial since it participates in the maintenance of local
homeostasis that is essential for epithelial regeneration (Pédron
et al., 2012). Similarly, the consumption of milk containing
L. casei BL23 in Balb/c mice also generated a significant increase
in Comamonas (Yin et al., 2014). Moreover, the significant
decrease in the Enterobacteriaceae family, that include genera
usually associated with pathogens (Klebsiella and Escherichia),
evidenced with both EPS also contributes to a more anti-
inflammatory and healthy gut state.
It can also be highlighted that results obtained with these EPS
differ from the results obtained with inulin that was included as a
positive prebiotic control. Fermentation of both EPS conducted
to a different SCFA profile and led to greater changes in the
microbial population after 72 h fermentation. In the DGGE
profiles obtained for glucose (a sugar easily fermentable by
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FIGURE 4 | Total SCFA (A) and individual acetate (B), propionate (C) and butyrate (D) levels of fecal homogenates fermented during 24, 48, and 72 h with and
without sugar source added. # indicates significant differences against carbohydrate-free basal medium at the same fermentation time. *indicates significant
differences between samples with a specific sugar at different fermentation time. (*/#p < 0.05, **/##p < 0.01, ***/###p < 0.001, Tukey’s multiple comparison test).
TABLE 2 | Short chain fatty acids (SCFA) concentration of the homogenates
fermented in basal medium with inulin at different times.
Fermentation time
24 h 48 h 72 h
Total SCFA (mM) 131.90 ± 0.67 150.25 ± 34.20 135.00 ± 12.51
Acetic acid (mM) 27.25 ± 1.33 31.41 ± 6.52 31.63 ± 2.91
Propionic acid (mM) 102.29 ± 0.41 116.21 ± 27.17 101.78 ± 9.55
Butyric acid (mM) 1.59 ± 0.21 2.63 ± 0.51 1.59 ± 0.17
Significant differences (p < 0.05, Tukey’s multiple comparison test) were no
detected at different fermentation times.
microorganisms that was included as control of bacterial growth
and activity) and inulin it can be observed a high percentage
of similarity between both sugars at 48 and 72 h fermentation
with practically identical band patterns. These similar patterns
obtained with inulin and glucose could be attributed to the fact
that the donors of fecal samples regularly consumed formula milk
with inulin, FOS or GOS, so their microbiota is probably adapted
to inulin-type prebiotics. These results highlight the relevance
of finding new compounds that can exert a beneficial effect on
the intestinal microbiota different from those observed with the
TABLE 3 | Isobutyric and isovaleric levels from homogenates fermented in basal







Basal medium 24 0.37 ± 0.03 a 0.24 ± 0.17 a
48 0.79 ± 0.13ab 0.45 ± 0.06a
72 1.15 ± 0.50b 0.90 ± 0.55a
Basal medium
with EPS8339
24 0.37 ± 0.12 a 0.20 ± 0.13a
48 1.28 ± 0.45 b 2.86 ± 1.74 b
72 3.03 ± 0.20 c 6.01 ± 0.65 c
Basal medium
with EPS38124
24 0.30 ± 0.09 a ND
48 1.30 ± 0.51 b 2.59 ± 1.26 b
72 2.27 ± 0.01 d 4.00 ± 0.012 b
ND, non-detected. Different letters indicate significant differences (p < 0.05,
Tukey’s multiple comparison test).
prebiotics commonly used in food in order to contribute to
establish a widely diverse intestinal microbiota usually associated
with a healthy state (Durack and Lynch, 2019). In this context, the
EPS produced by L. paracasei CIDCA 8339 and CIDCA 83124
emerge as alternative potential prebiotics that can be fermented
by the fecal microbiota in vitro, producing modifications in
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the DGGE microbiological profile after 72 h that differs from
the changes induced by inulin. Additionally, in contrast to
inulin that induced mainly the production of propionate, the
fermentation of EPS8339 and EPS83124 led to a significant increase
in butyrate levels, a bioactive metabolite with several beneficial
effects at the intestinal level. It is remarkable that, even though
bacterial EPS8339 and EPS83124 required 72 h fermentation to
induce changes in microbial population, they rapidly modified
microbiota activity as can be evidenced by the increase in
SCFA after 24 h. Considering this, both EPS could be used as
complementary prebiotics that contribute to consumers’ health
inducing favorable changes at the intestinal microbiota that are
different from the ones induced by inulin.
The increase of butyrate as a consequence of EPS8339 and
EPS83124 fermentation may bring a wide range of health benefits,
particularly at the intestinal level. Butyrate can be used as
an energy source by enterocytes (van der Beek et al., 2015).
Moreover, it contributes to strengthen the intestinal epithelial
barrier through a mechanism that involves the induction of tight
junctions’ proteins expression such as Claudin 1 and ZO-1 and
their redistribution in the membrane (Morrison and Preston,
2016). The loss of integrity of the intestinal barrier and the
consequent increase in its permeability is generally associated
with an increase in bacterial translocation and/or its wall
components, which results in a mild chronic inflammatory state
that has been associated with pathologies such as obesity, insulin
resistance and diabetes type 2 (Cani et al., 2008; Qin et al., 2012).
Furthermore, propionate production would also be beneficial
in people that suffer of obesity since it inhibits cholesterol
synthesis at the liver, regulates lipogenesis in adipose tissue (Ríos-
Covián et al., 2016; Tsai et al., 2019) and regulates appetite
through the expression of leptin, PYY and GLP-1 (Chambers
et al., 2015). Thus, the use of prebiotics that leads to the
production of butyrate and/or propionate at the intestinal level
results interesting in individuals with these kinds of metabolic
disorders. On the other hand, SCFA regulate the immune
response at the intestinal level, contributing to the healthy state
in patients suffering from inflammatory bowel diseases. Butyrate,
for instance, exerts an anti-inflammatory effect by inhibiting
the activation of the transcription factor NFκB in macrophages
and the expression of proinflammatory cytokines (IL-6 and IL-
12) in dendritic cells. Moreover, butyrate and propionate are
able to regulate the production and function of regulatory T
cells by inhibiting histone deacetylases (Morrison and Preston,
2016; Requena et al., 2018). Dysbiosis observed in inflammatory
bowel diseases, including ulcerative colitis and Crohn’s disease,
is generally associated with a reduction in SCFA levels (Alagón
Fernández del Campo et al., 2019) and an increase in species of
the Enterobacteriaceae family and other opportunistic pathogens
(Gonçalves et al., 2018; Uchiyama et al., 2019). The microbiota
modulation favoring the production of SCFA during infancy is
relevant to reduce the risk of disease development in the future.
In this context, Roduit et al. (2019) studied the role of SCFA in
the prevention of allergy and asthma by analyzing SCFA levels in
1-year-old children fecal samples and correlating them with the
development of disease when those children were 6 years old. The
authors evidenced that children that presented the highest levels
of propionate and/or butyrate when they were 1 year old, were
less likely to develop asthma, food allergy and allergic rhinitis
when they grew up. In the same way, it has been suggested that
butyrate-producing bacteria play a key role in reducing the risk
of developing type 1 diabetes in children between 1 and 5 years
old (de Goffau et al., 2014).
This study revealed that the EPS produced by L. paracasei
CIDCA 8339 and CIDCA 83124 isolated from kefir induce
substantial distinct effects on fecal microbiota activity and
composition of healthy children leading to selective enrichments
of those microorganisms that possess the ability to adapt
their growth to the respective substrates. Mass sequencing
analysis demonstrated that the fermentation of EPS8339 leads
to an increase in the proportion of the genera Victivallis,
Acidaminococcus, and Comamonas and a significant drop
in the proportion of enterobacteria. In the same direction,
the fermentation of the EPS83124 also resulted in a marked
reduction in the population of Enterobacteriaceae with a
significant increase in the genus Comamonas. These responses
were linked to directed changes in SCFA toward butyrate
production in higher concentration than controls. It was
observed that both EPS presented a different fermentation profile
probably due to differences in their structural characteristics.
EPS8339 fermentation led to an increment of propionate and
butyrate, while fermentation of EPS83124 increased mainly
butyrate levels. These increase in the production of propionate
and/or butyrate, accompanied by a decrease in the population
of Enterobacteriaceae allowed us to hypothesize that the
consumption of both EPS could contribute to reduce the
inflammation at the intestinal level.
Although fecal microbiota composition partially correlates
with gut microbiota, these results are a first step in the knowledge
of the ability of two EPS from L. paracasei strains isolated
from kefir to be fermented by human microbiota. It can be
concluded that the EPS synthesized by L. paracasei CIDCA8339
and CIDCA83124 in milk can be considered bioactive compounds
that modify the microbiota increasing the production of
propionic and/or butyric acid, two metabolites highly associated
with beneficial effects both at the gastrointestinal and extra-
intestinal level.
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